Advisornet Financial’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $142K | Sell |
4,201
-720
| -15% | -$24K | 0.01% | 749 |
|
|
2026
Q1 | $148K | Sell |
4,921
-69
| -1% | -$2.22K | 0.01% | 693 |
|
|
2025
Q4 | $156K | Hold |
4,990
| – | – | 0.01% | 673 |
|
|
2025
Q3 | $101K | Hold |
4,990
| – | – | 0.01% | 787 |
|
|
2025
Q2 | $83.6K | Buy |
4,990
+513
| +11% | +$8.28K | 0.01% | 810 |
|
|
2025
Q1 | $68.8K | Hold |
4,477
| – | – | 0.01% | 830 |
|
|
2024
Q4 | $98.7K | Sell |
4,477
-200
| -4% | -$3.64K | 0.01% | 694 |
|
|
2024
Q3 | $84.3K | Sell |
4,677
-1,000
| -18% | -$17.5K | 0.01% | 743 |
|
|
2024
Q2 | $92.3K | Hold |
5,677
| – | – | 0.01% | 666 |
|
|
2024
Q1 | $80.1K | Hold |
5,677
| – | – | 0.01% | 692 |
|
|
2023
Q4 | $59.3K | Sell |
5,677
-2,431
| -30% | -$22.7K | 0.01% | 764 |
|
|
2023
Q3 | $82.7K | Buy |
8,108
+4,500
| +125% | +$41.9K | 0.01% | 662 |
|
|
2023
Q2 | $27.2K | Buy |
3,608
+660
| +22% | +$5.35K | ﹤0.01% | 987 |
|
|
2023
Q1 | $26.1K | Hold |
2,948
| – | – | ﹤0.01% | 983 |
|
|
2022
Q4 | $26.9K | Hold |
2,948
| – | – | ﹤0.01% | 964 |
|
|
2022
Q3 | $24K | Buy |
2,948
+1,458
| +98% | +$12.9K | ﹤0.01% | 1058 |
|
|
2022
Q2 | $11K | Buy |
1,490
+1,413
| +1,835% | +$12.3K | ﹤0.01% | 1320 |
|
|
2022
Q1 | $1K | Hold |
77
| – | – | ﹤0.01% | 1934 |
|
|
2021
Q4 | $1K | Buy |
77
+73
| +1,825% | +$659 | ﹤0.01% | 1967 |
|
|
2021
Q3 | $0 | Hold |
4
| – | – | ﹤0.01% | 1997 |
|
|
2021
Q2 | $0 | Hold |
4
| – | – | ﹤0.01% | 1862 |
|
|
2021
Q1 | $0 | Sell |
4
-350
| -99% | -$4.01K | ﹤0.01% | 1827 |
|
|
2020
Q4 | $3K | Hold |
354
| – | – | ﹤0.01% | 1520 |
|
|
2020
Q3 | $3K | Buy |
354
+205
| +138% | +$2.17K | ﹤0.01% | 1519 |
|
|
2020
Q2 | $2K | Hold |
149
| – | – | ﹤0.01% | 1618 |
|
|
2020
Q1 | $1K | Sell |
149
-500
| -77% | -$5.12K | ﹤0.01% | 1717 |
|
|
2019
Q4 | $6K | Sell |
649
-3,016
| -82% | -$26.9K | ﹤0.01% | 1509 |
|
|
2019
Q3 | $25K | Buy |
3,665
+1,525
| +71% | +$11.7K | ﹤0.01% | 1129 |
|
|
2019
Q2 | $20K | Hold |
2,140
| – | – | ﹤0.01% | 1052 |
|
|
2019
Q1 | $34K | Sell |
2,140
-50
| -2% | -$882 | ﹤0.01% | 846 |
|
|
2018
Q4 | $34K | Sell |
2,190
-450
| -17% | -$9.22K | ﹤0.01% | 779 |
|
|
2018
Q3 | $57K | Hold |
2,640
| – | – | 0.01% | 689 |
|
|
2018
Q2 | $64K | Hold |
2,640
| – | – | 0.01% | 651 |
|
|
2018
Q1 | $45K | Sell |
2,640
-438
| -14% | -$8.55K | 0.01% | 723 |
|
|
2017
Q4 | $58K | Buy |
+3,078
| New | +$46.3K | 0.01% | 613 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
Advisornet Financial's TEVA Position: Q2 2026 in Review
Advisornet Financial reduced its Teva Pharmaceuticals (TEVA) stake by 15% in Q2 2026, selling an estimated $24K and leaving 4,201 shares worth $142K. The position accounts for 0.01% of the portfolio, ranked #749.
Advisornet Financial first reported a position in TEVA in Q4 2017 and has held it in 35 quarters since. The position peaked at $156K in Q4 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Advisornet Financial held 4,201 shares of Teva Pharmaceuticals worth $142K as of Q2 2026.
- Advisornet Financial sold 720 Teva Pharmaceuticals shares in Q2 2026, an estimated $24K.
- Teva Pharmaceuticals made up 0.01% of Advisornet Financial's portfolio in Q2 2026, its #749 holding.
- Advisornet Financial first reported a position in Teva Pharmaceuticals in Q4 2017 and has held it in 35 quarters since.
- Advisornet Financial's Teva Pharmaceuticals position peaked at $156K in Q4 2025.
- 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on Advisornet Financial's 13F filing for Q2 2026, filed 23 Jul 2026.